Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: EGFR-Mutant Lung Cancer Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

NCT02349633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PF-06747775, Palbociclib, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01526928
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Interventions
Rociletinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
39
States / cities
Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1 Interventional

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

NCT04479306
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Alisertib, Osimertinib, Sapanisertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 2 Interventional Results available

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

NCT04971187
View directory record Official record
Conditions
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions
Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 3 Interventional Results available

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NCT05493501
View directory record Official record
Conditions
NSCLC
Interventions
Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine
Drug
Lead sponsor
EQRx International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 2 Interventional Results available

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

NCT02770014
View directory record Official record
Conditions
Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jul 24, 2026, 6:11 AM EDT
Not yet recruiting Phase 3 Interventional

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
34
States / cities
Beverly Hills, California • Fullerton, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

NCT02364609
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Afatinib Dimaleate, Pembrolizumab
Drug · Biological
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1 Interventional

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

NCT01967095
View directory record Official record
Conditions
EGFR-Mutant Lung Cancer
Interventions
erlotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

NCT04120454
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Pembrolizumab, Ramucirumab
Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

NCT02155465
View directory record Official record
Conditions
Lung Cancer
Interventions
Ruxolitinib, Erlotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 24, 2026, 6:11 AM EDT
Withdrawn No phase listed Observational

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

NCT05116618
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
InVisionFirst-Lung ctDNA assay
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 1 Interventional

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

NCT05153408
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
Interventions
BLU-701, osimertinib, carboplatin, pemetrexed
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 24, 2026, 6:11 AM EDT
Active, not recruiting Phase 3 Interventional

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

NCT02193282
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Clinical Observation, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1403
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 1 Interventional

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

NCT02342353
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Pacritinib, Erlotinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT02535338
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Onalespib Lactate, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1 Interventional

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

NCT02520778
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Navitoclax, Osimertinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 24, 2026, 6:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

NCT04486833
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy
Biological · Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 3 Interventional Results available

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

NCT02322281
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Bakersfield, California • Duarte, California • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 24, 2026, 6:11 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

NCT07462377
View directory record Official record
Conditions
Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR
Interventions
EPI-326
Drug
Lead sponsor
EpiBiologics
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Los Angeles, California • East Brunswick, New Jersey • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

NCT02321540
View directory record Official record
Conditions
Lung Cancer
Interventions
Ibrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jul 24, 2026, 6:11 AM EDT
Withdrawn No phase listed Observational

PDX Models From EGFR Mutant Tumors

NCT03872440
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Jul 24, 2026, 6:11 AM EDT
Terminated Phase 2 Interventional Results available

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

NCT03292133
View directory record Official record
Conditions
Lung Cancer
Interventions
EGF816, Gefitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 24, 2026, 6:11 AM EDT
Completed Phase 1 Interventional Results available

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

NCT02789345
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Ramucirumab, Necitumumab, Osimertinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jul 24, 2026, 6:11 AM EDT